Moderna Inc. (MRNA): Price and Financial Metrics
MRNA Price/Volume Stats
Current price | $110.59 | 52-week high | $163.24 |
Prev. close | $107.41 | 52-week low | $62.55 |
Day low | $105.04 | Volume | 4,575,100 |
Day high | $111.13 | Avg. volume | 4,421,445 |
50-day MA | $99.03 | Dividend yield | N/A |
200-day MA | $100.48 | Market Cap | 42.34B |
MRNA Stock Price Chart Interactive Chart >
MRNA POWR Grades
- Value is the dimension where MRNA ranks best; there it ranks ahead of 86.42% of US stocks.
- MRNA's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- MRNA's current lowest rank is in the Sentiment metric (where it is better than 3.18% of US stocks).
MRNA Stock Summary
- MODERNA INC's market capitalization of $41,399,816,286 is ahead of 93.72% of US-listed equities.
- Of note is the ratio of MODERNA INC's sales and general administrative expense to its total operating expenses; only 9.66% of US stocks have a lower such ratio.
- Revenue growth over the past 12 months for MODERNA INC comes in at -57.36%, a number that bests merely 4.05% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to MODERNA INC, a group of peers worth examining would be SYBX, LIFE, MGNX, SYRS, and SEEL.
- MRNA's SEC filings can be seen here. And to visit MODERNA INC's official web site, go to www.modernatx.com.
MRNA Valuation Summary
- MRNA's price/sales ratio is 4.2; this is 90.91% higher than that of the median Healthcare stock.
- MRNA's EV/EBIT ratio has moved up 4.5 over the prior 62 months.
Below are key valuation metrics over time for MRNA.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
MRNA | 2023-12-29 | 4.2 | 2.8 | -10.9 | -15.4 |
MRNA | 2023-12-28 | 4.1 | 2.8 | -10.9 | -15.3 |
MRNA | 2023-12-27 | 4.2 | 2.9 | -11.1 | -15.6 |
MRNA | 2023-12-26 | 4.1 | 2.8 | -10.7 | -15.0 |
MRNA | 2023-12-22 | 4.0 | 2.7 | -10.4 | -14.6 |
MRNA | 2023-12-21 | 3.8 | 2.6 | -10.0 | -14.0 |
MRNA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MRNA has a Quality Grade of A, ranking ahead of 98.11% of graded US stocks.
- MRNA's asset turnover comes in at 0.829 -- ranking 29th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows MRNA's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.829 | 0.859 | 4.068 |
2021-06-30 | 0.688 | 0.865 | 4.248 |
2021-03-31 | 0.388 | 0.926 | 0.804 |
2020-12-31 | 0.183 | 0.990 | -0.511 |
2020-09-30 | 0.084 | 1.000 | -0.360 |
2020-06-30 | 0.048 | 1.000 | -0.322 |
MRNA Price Target
For more insight on analysts targets of MRNA, see our MRNA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $286.15 | Average Broker Recommendation | 1.84 (Hold) |
Moderna Inc. (MRNA) Company Bio
Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to produce an immune response. (Source:Wikipedia)
Latest MRNA News From Around the Web
Below are the latest news stories about MODERNA INC that investors may wish to consider to help them evaluate MRNA as an investment opportunity.
Tech Stalls As Rising Bond Yields Spook InvestorsIt's been an inauspicious start to the 2024 trading year, with all three major indexes in the red midday. |
The Biggest Losers in S&P 500 This Year: Dollar General, Moderna, and MoreThe five worst performers in the market benchmark so far this year could be set for brighter futures. |
Walgreens, Nike, Moderna: Bargain hunting stocksThe most recent bull market run has been widely described as "weird," with several household stocks underperforming during the bull run on S&P 500 (^GSPC) components. Yahoo Finance Reporter Madison Mills showcases three of these companies — Moderna (MRNA), Walgreens (WBA), and Nike (NKE) — where investors may find the most value for a bargain price on the stocks. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. |
S&P 500 Is Nearing a Record High. This Could Derail It in 2024.Microsoft and OpenAI are sued by the New York Times for copyright infringement, Amazon plans to launch adverts on Prime Video next month, and other news to start your day. |
The Winners and Losers: 2023 Stock Market Performance ReviewThe 2023 stock market saw steep declines followed by rapid upswings, but we're ending the year on a high note (even if some stocks aren't). |
MRNA Price Returns
1-mo | 14.96% |
3-mo | 11.20% |
6-mo | 7.07% |
1-year | -25.68% |
3-year | -10.40% |
5-year | 443.44% |
YTD | 11.20% |
2023 | -44.63% |
2022 | -29.28% |
2021 | 143.11% |
2020 | 434.10% |
2019 | 28.09% |
Loading social stream, please wait...